A PHASE 3, RANDOMIZED, PARTIALLY DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY TODDLERS 12 THROUGH 23 MONTHS OF AGE WITH 2 PRIOR INFANT DOSES OF PREVENAR 13
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Pneumococcal 20-valent conjugate vaccine (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Pfizer
Most Recent Events
- 06 Jul 2023 Status changed from active, no longer recruiting to completed.
- 30 May 2023 Planned End Date changed from 8 Jun 2023 to 1 Jun 2023.
- 30 May 2023 Planned primary completion date changed from 8 Jun 2023 to 1 Jun 2023.